Prostate cancer screening with prostate-specific antigen: Where are we going?

Current prostate-specific antigen screening is not cost-effective from a public health perspective. A new algorithm using genetic testing and imaging has yet to be developed. See also pages 000-000.

http://ift.tt/2ANQ3xP